Clinical Trials Browser

INDUSTRY × Interventional × abemaciclib × Clear all

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT04802759 2026-03-16

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT05440786 2026-03-12

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Phase 2 Active not recruiting

46 enrolled 19 charts

Neoplasm Metastasis, Sarcoma, Ewing

NCT07100106 2026-03-12

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT04931342 2026-03-10

BOUQUET

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT06065748 2026-03-09

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07174336 2026-03-06

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Phase 1 Completed

Prostatic Neoplasms

NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Phase 1/2 Completed

47 enrolled 36 charts

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT05307705 2026-03-02

PIKASSO-01

Phase 1 Active not recruiting

Breast Neoplasms

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06188520 2026-02-24

CYCAD-1

Phase 1/2 Recruiting

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT05548127 2026-02-10

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT02152631 2026-02-06

JUNIPER

Phase 3 Active not recruiting

453 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT02747004 2026-02-06

Next MONARCH 1

Phase 2 Active not recruiting

234 enrolled 20 charts

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

Phase 3 Active not recruiting

463 enrolled 20 charts

Breast Neoplasms

NCT05386108 2026-02-05

ELECTRA

Phase 1/2 Recruiting

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT02246621 2026-02-03

MONARCH 3

Phase 3 Active not recruiting

493 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT06810544 2026-02-02

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Phase 1/2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Glioma, Lung Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

Breast Neoplasms

NCT02779751 2026-01-26

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05696626 2026-01-26

ELAINEIII

Phase 3 Recruiting

Breast Neoplasms

NCT04964934 2026-01-16

SERENA-6

Phase 3 Active not recruiting

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05169567 2026-01-16

postMONARCH

Phase 3 Active not recruiting

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

Breast Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT02107703 2025-10-21

MONARCH 2

Phase 3 Active not recruiting

669 enrolled 22 charts 1 FDA

Breast Neoplasms

NCT05735080 2025-09-19

INX-315-01

Phase 1/2 Recruiting

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

94 enrolled 28 charts

BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

NCT04752332 2025-07-15

eMonarcHER

Phase 3 Terminated

111 enrolled 9 charts

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

Phase 3 Active not recruiting

874 enrolled 29 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT06570031 2025-07-02

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT05288166 2025-06-27

CYCLONE 3

Phase 3 Active not recruiting

925 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT03099174 2025-06-24

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Phase 1 Completed

133 enrolled 26 charts

Breast Neoplasms, Neoplasms

NCT05952557 2025-06-19

CAMBRIA-2

Phase 3 Recruiting

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

Phase 1 Active not recruiting

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT03155997 2025-04-20

monarchE

Phase 3 Active not recruiting

5,637 enrolled 12 charts 2 FDA

Breast Neoplasms

NCT03706365 2025-04-20

CYCLONE 2

Phase 2/3 Active not recruiting

393 enrolled 23 charts

Prostatic Neoplasms

NCT04432454 2025-02-13

ELAINEII

Phase 2 Completed

Breast Neoplasms

NCT02675231 2024-11-26

monarcHER

Phase 2 Completed

237 enrolled 25 charts

Hormone Receptor Positive Breast Cancer

NCT02791334 2024-09-27

PACT

Phase 1 Completed

BreastDermatologicGastrointestinal

Breast Neoplasms, Melanoma, Pancreatic Neoplasms

NCT01394016 2024-09-19

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Phase 1 Completed

225 enrolled 31 charts

Advanced Cancer

NCT04408924 2024-06-25

CYCLONE 1

Phase 2 Completed

44 enrolled 21 charts

Metastatic Castration-Resistant Prostate Cancer

NCT04092673 2024-05-21

Zotatifin

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT03703466 2024-04-02

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

Phase 2 Completed

72 enrolled 19 charts

Breast Neoplasms

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

Breast Neoplasms

NCT01739309 2023-09-21

Study of LY2835219 for Mantle Cell Lymphoma

Phase 2 Completed

28 enrolled 20 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell